Vol 43, Issue 8

In this CME article, explore why migraine often coexists with depression and anxiety, and get practical tips for diagnosis, prevention, and smarter prescribing.

FDA acceptance of mitragynine IND launches NIH phase 1 trial for opioid use disorder, tracking safety, dosing, and PK amid new DEA scheduling moves.

Long-acting injectable buprenorphine cuts missed doses, boosts retention, and protects patients during high-risk transitions in the fentanyl era.

Urine drug screenings are often misordered and misread, risking stigma and harm; learn immunoassay limits, confirmatory testing basics, and when testing truly helps.

Learn why varenicline leads smoking cessation products in bipolar disorder, with reassuring safety data and practical strategies when quitting proves difficult.

Remote, home-based tDCS shows modest symptom relief and higher remission in major depression, with generally good safety but burn risks to watch.

Real‑world inpatient use of xanomeline/trospium shows rapid awakening from negative symptoms in schizophrenia, with response predictors and striking case insights.

"...time slowed to the tide’s rhythm and the surf’s roar, each day closed by a Great Horned Owl’s silent fly-by at dusk..."

Why modern psychiatry risks missing the person: It's time to revive biopsychosocial, cultural, and spiritual history beyond DSM checklists and EHR bloat.

Explore new consensus guidelines on childhood stuttering, uniting psychiatry and neurology with practical treatment insights to improve patient care.

STARS experts redefine stuttering as a brain-based neuropsychiatric disorder, urging interdisciplinary care and warning dopamine-boosting ADHD or antidepressant meds may worsen symptoms.